AbbVie made a $350 million upfront payment to Gubra for rights to the drug, called GUB014295. Gubra is also eligible to receive another $1.9 billion if certain development and sales milestones are met ...

Five years after the start of the pandemic, the fight over who owns the underlying technologies that made the Covid-19 ...

Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U ...

“The companies told the PTAB in the petitions that Moderna’s patents include ‘unimaginably broad claims directed to a basic idea.’” Patent Trial and Appeal Board (PTAB) docket entries ...

U.S. health officials are reevaluating a $590 million contract that was awarded to Moderna for the development of its bird flu vaccine, Bloomberg News reported on Wednesday, citing sources.

Moderna Inc. expects to launch a personalized cancer vaccine that it’s developing with Merck & Co. by 2027, one of its top ...

(Reuters) -Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a rare neurological side effect was reported. The trial of the ...

A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological disorder. The phase 3 study is evaluating the candidate, dubbed mRNA-1403 ...

Moderna did not include potential sales for new products, including its next-generation Covid-19 vaccine, in its 2025 estimates. The team was asked whether this was a reflection of any uncertainty ...

MORE: Moderna awarded $590M to help accelerate development of mRNA-based bird flu vaccine: HHS In this small, preliminary trial of 16 patients, half had a strong immune response to the vaccine.

The FDA canceled a vaccine advisory committee meeting to discuss influenza virus strains that should be included in shots for the next flu season ...

Moderna (MRNA) stock in focus as the company aims a 2027 marketing nod for Merck (MRK) partnered skin cancer vaccine. Read ...